-
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Not Recruiting
More
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to
Choline, for a prospective single-center, single-arm study for participants with suspected
parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Stanford Investigators
View full details
-
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
Recruiting
More
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in
combination with Standard of Care, versus Standard of Care alone, in adult male patients with
mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed
Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in
this study.
Stanford Investigators
View full details
-
Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Not Recruiting
More
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to
identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Stanford is currently not accepting patients for this trial.
For more information, please contact Roan C Raymundo, BS, 650-721-4071.
Stanford Investigators
View full details
-
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Not Recruiting
More
Prostate cancer (PC) remains the most-common non-cutaneous cancer diagnosed in American
males, accounting for an estimated 174,560 estimated new cases and 31,620 estimated deaths in
2019. Up to 40% of the patients with prostate cancer develop biochemical recurrence within 10
years after initial treatment. Usually an increase of the prostate-specific antigen (PSA)
llevel precedes a clinically detectable recurrence by months to years, and this is currently
used as a screening test before and subsequent to treatment. However, disease advancement can
be local, regional or systemic, and each has significantly different approaches to disease
management. Unfortunately, PSA level does not differentiate between these disease stages.
This phase 2-3 study explores the utility of radiolabel 68Ga-RM2, a 68-gallium (68Ga)-labeled
gastrin-releasing peptide receptor (GRPr) antagonist, for positron emission tomography (PET)
/ magnetic resonance imaging (MRI) (collectively, PET/MRI) as a potential tool to help
discriminate between disease stages in participants after treatment with surgery or
radiation, who present persistently elevated PSA levels (ie, may have prostate cancer), but
were negative for cancer with a diagnostic regular medical care computed tomography (CT) scan
68Ga-RM2 (BAY86-7548) is also identified as a synthetic bombesin receptor antagonist. PET/MRI
is the collective result of 2 scan processes (PET and MRI ) conducted during the same scan
procedure (ie, a combined scan). After a regular medical care computed tomography (CT) scan,
participants will be scanned with 68Ga-RM2 PET/MRI scan procedure. PET/MRI is used to assess
the location, size, and metabolic activity of a suspected tumor.
The 68Ga-RM2 radiolabel consisted of a ligand (the synthetic bombesin receptor antagonist)
and the radioisotope 68Ga. The RM2 ligand targets gastrin-releasing peptide receptors (GRPr),
commonly expressed by prostate cancer cells, and the radioisotope distinguishes those cells
from the background. The criteria for scan "positivity" will be, when compared to background
level of the liver (control), the 68Ga signal is stronger (positive - malignant) or weaker
(negative - benign).
This study will assess how well 68Ga-RM2 works in detecting prostate cancer in patients with
68Ga-RM2 PET/MRI may be able to see smaller tumors than the standard of care
contrast-enhanced CT or MRI scan.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pamela Gallant, 650-725-6409.
Stanford Investigators
View full details
-
Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Not Recruiting
More
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular
imaging agent in patients with (metastatic) pancreas cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alexander A Valencia, 650-498-5185.
Lead Sponsor
Stanford Investigators
View full details
-
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Not Recruiting
More
This study is being conducted to determine whether the combination of imaging agents 68-Ga
RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy
than standard imaging or biopsy in patients with known prostate cancer (PC)
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Stanford Investigators
View full details
-
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Not Recruiting
More
This phase II trial studies how well gallium Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2
positron emission tomography (PET)/magnetic resonance imaging (MRI) work in diagnosing
participants with prostate cancer that has come back. Diagnostic procedures, such as gallium
Ga 68 DOTA-NeoBOMB1 and gallium Ga 68 PSMA-R2 PET/MRI, may help find and diagnose prostate
cancer and find out how far the disease has spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrei Iagaru, 650-725-4711.
Stanford Investigators
View full details
-
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake
Recruiting
More
The purpose of this first-in-human (FIH) study of [177Lu]-NeoB is to characterize the safety,
tolerability, pharmacokinetics (PK) as well as the distribution and radiation dosimetry, and
anti-tumor activity of [177Lu]-NeoB in patients with advanced solid tumors known to
overexpress GRPR and with [68Ga]-NeoB lesion uptake.
Stanford Investigators
View full details
-
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Not Recruiting
More
This study is being conducted to determine whether the combination of imaging agents 68-Ga
RM2 and 68-Ga PMSA11 is better at assessing response to high intensity focused ultrasound
(HIFU) or high dose rate (HDR) local therapy than standard imaging or biopsy in patients with
known prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shahryar Niknam, 650-721-4080.
Stanford Investigators
View full details
-
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
Not Recruiting
More
This Phase 1/2 study is intended to investigate the safety, tolerability, and radiation
dosimetry of 177Lu-PSMA-R2 and further assess preliminary efficacy data in patients with
metastatic castration-resistant prostate cancer (mCRPC). The Phase 1 portion of the study
will determine the recommended dose of 177Lu-PSMA-R2 for radio-ligand therapy (RLT) of mCRPC,
and the Phase 2 portion will expand into approximately 60 patients documenting the
preliminary activity (anti-tumor response) of repeated treatments administered, continuing
safety assessments and collecting QoL data.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Not Recruiting
More
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen
receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
Stanford is currently not accepting patients for this trial.
For more information, please contact Shahyar Niknam, 408-721-4080.
Stanford Investigators
View full details
-
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Not Recruiting
More
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for
biopsy guidance in patients with suspected prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jordan Cisneros, 650-498-7061.
Stanford Investigators
View full details
-
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Recruiting
More
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis,
and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
Lead Sponsor
Stanford Investigators
View full details
-
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Not Recruiting
More
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying
cancer that has spread to the lymph nodes in patients with squamous cell head and neck
cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during
surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount
of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans
make detailed, computerized pictures of areas inside the body where the drug is used. Giving
panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help
doctors find metastatic lymph nodes better than current methods [positron emission tomography
(PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations].
Stanford is currently not accepting patients for this trial.
For more information, please contact Eben L. Rosenthal, 650-723-2967.
Stanford Investigators
View full details
-
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Not Recruiting
More
This study provides fluorine F 18 DCFPyL positron emission tomography/computed tomography
(PET/CT) to participants with prostate cancer that has come back. Diagnostic procedures, such
as fluorine F 18 DCFPyL PET/CT, may help find and diagnose prostate cancer and find out how
far the disease has spread.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrei Iagaru, 650-725-4711.
Stanford Investigators
View full details
-
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CT
Not Recruiting
More
Rituximab is an antibody targeted against the CD20 antigen found primarily on B-cells.
Therefore, an imaging agent targeting CD20 expression may provide a more accurate evaluation
of extent of disease and response to therapy than the current standard of care, F-18 FDG
PET/CT.
The main purpose of the study is to investigate a new PET/CT imaging probe for detection and
follow up of lymphoma. Following are the 3 aims of the study: a) Phase I testing in lymphoma
patients of Cu-64 labelled Rituxan for defining normal tracer biodistribution, stability,
pharmacokinetics and radiation dosimetry; b) comparison of Cu-64 Rituxan and F-18 FDG PET/CT
in lymphoma patients; c) evaluation of changes in uptake of Cu-64 Rituxan in response to
rituximab-based treatment in CD20-positive B-cell NHL
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Chitouras, 6504980623.
Stanford Investigators
View full details
-
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Not Recruiting
More
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and
monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors,
medullary thyroid cancer and other cancers expressing somatostatin receptors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amanda Remillard, 650-721-4091.
Stanford Investigators
View full details
-
68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
Not Recruiting
More
This phase II trial studies how well gallium Ga 68-labeled gastrin-releasing peptide receptor
(GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/computed
tomography (CT) works in detecting regional nodal and distant metastases in patients with
intermediate or high-risk prostate cancer. 68Ga-RM2 PET/CT scan may be able to see smaller
tumors than the standard of care CT or magnetic resonance imaging scan.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jordan Cisneros, 650-725-4711.
Stanford Investigators
View full details
-
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
Not Recruiting
More
This pilot clinical trial studies the use of integrin alpha-v-beta [18F]-R01-MG-F2 Positron
Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic
Resonance Imaging in (PET/MRI) in measuring response in patients with pancreatic cancer and
healthy volunteers. Integrins, such as integrin alpha-v-beta-6 (avb6), are a family of
membrane receptors that are overexpressed on the cell surface of pancreatic cancers.
[18F]-R01-MG-F2 targets avb6, which may improve early detection of and better stratify
treatment options for patients with pancreatic cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Krithika Rupnarayan, 650-736-0959.
Lead Sponsor
Stanford Investigators
View full details
-
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Not Recruiting
More
The purpose of this study is to compare progression-free survival (PFS) (based upon
investigator assessment using RECIST v1.1) in participants with platinum-resistant ovarian
cancer who receive combination therapy with EC145 and pegylated liposomal doxorubicin
(EC145+PLD) with that in participants who receive PLD and placebo.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sharanya Ramasubramanian, 650-723-0622.
Stanford Investigators
View full details
-
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
Not Recruiting
More
The investigators will evaluate the detection of cardiac sarcoidosis or inflammation using
18F-FSPG PET/MRI (or PET/CT for participants with metal implants).
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrea Otte, DPT, 650-736-4183.
Lead Sponsor
Stanford Investigators
View full details
-
Standard PET/CT vs. Digital PET/CT
Not Recruiting
More
The investigators wish to determine if standard and digital PET/CT scanners provide
equivalent results for disease detection and diagnosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT
Not Recruiting
More
Accurate measurements from a non-invasive test like myocardial perfusion positron emission
tomography/ computed tomography (PET/CT) may decrease the need for invasive procedures such
as cardiac catheterization.The investigators wish to see if the measurements from cardiac
catheterization can be predicted using a non-invasive 13N-NH3 digital PET/CT scan.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jordan Ciscernos, 650-725-6409.
Lead Sponsor
Stanford Investigators
View full details
-
Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals
Not Recruiting
More
This clinical trial studies how well positron emission tomography (PET)/computed tomography
(CT) works compared to PET/magnetic resonance imaging (MRI) in evaluating patients with
cancer. PET/CT and PET/MRI may determine which scanner is best for the patient's type of
cancer and other types of cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
Lead Sponsor
Stanford Investigators
View full details
-
Yttrium-90 (Y90) Glass Microspheres PET/CT in Imaging Patients With Liver Tumors
Not Recruiting
More
This clinical trial studies how well yttrium-90 (Y90) glass microspheres positron emission
tomography (PET)/computed tomography (CT) works in imaging patients with liver tumors .
Images produced by PET/CT may provide better information about the distribution of particles,
such as Y90 glass microspheres, delivered for selective internal radiation therapy (SIRT) as
compared to regular medical care images useing technetium Tc-99m albumin-aggregated single
photon emission computed tomography (SPECT)/CT images.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
Not Recruiting
More
The purpose of this research study is to see if recurrent prostate cancer can be identified
using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to
describe information regarding the function, as well as location and size of a tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Omar Rutledge, 650-721-4089.
Stanford Investigators
View full details
-
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
Not Recruiting
More
This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent
for positron emission tomography (PET)/magnetic resonance imaging (MRI), collectively
PET-MRI, in patients with prostate cancer. PET uses a radioactive substance called
68Ga-DOTA-Bombesin, which attaches to tumor cells with specific receptors on their surfaces.
The PET scanner takes pictures that capture where the radioactive drug is "lighting up" and
attaching to tumor cells, which may help doctors recognize differences between tumor and
healthy prostate tissue. MRI uses radio waves and a magnet to make a picture of areas inside
the body. Using 68Ga-DOTA-Bombesin in diagnostic procedures, such as PET/MRI, may allow
doctors to identify smaller tumors than standard imaging.
Stanford is currently not accepting patients for this trial.
For more information, please contact Phuong Pham, 650-725-9810.
Lead Sponsor
Stanford Investigators
View full details
-
18F-FSPG PET/CT for Cancer Patients on Therapy
Not Recruiting
More
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG
used before and after treatment to diagnose, predict, and evaluate response to therapy in
patients with a wide variety of metastatic cancers.
Stanford is currently not accepting patients for this trial.
For more information, please contact Phuong Pham, 650-725-9810.
Stanford Investigators
View full details
-
NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer
Not Recruiting
More
This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/
fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging
(MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating
patients with prostate cancer that has not responded to hormone therapy and has spread to
other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors
accurately measure how well patients respond to treatment with radium Ra 223 dichloride.
Stanford is currently not accepting patients for this trial.
For more information, please contact Omar Rutledge, 650-721-4089.
Lead Sponsor
Stanford Investigators
View full details
-
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
Not Recruiting
More
This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane
antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to
find tumors in patients with prostate cancer who are undergoing resection surgery for
prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is
likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help
find and diagnose prostate cancer, and reveal out how far the disease has spread. Radioactive
drugs, such as 68Ga-PSMA-11, may bind to tumor cells that have specific receptors, and may
allow doctors to see smaller tumors than the standard of care contrast-enhanced computed
tomography (CT) or MRI scan.
Stanford is currently not accepting patients for this trial.
For more information, please contact Omar Rutledge, 650-721-4089.
Stanford Investigators
View full details
-
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Not Recruiting
More
This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F)
fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance
imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or
stage II-IV prostate cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Risa Jiron, 650-736-1598.
Lead Sponsor
Stanford Investigators
View full details
-
Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer
Not Recruiting
More
The investigators hope to learn whether perfusion CT is a useful way to assess primary
cervical tumor microenvironment and whether there is a relationship between pretreatment
perfusion CT measurements and primary cervical tumor size, lymph node involvement (as
assessed by standard of care pretreatment fludeoxyglucose Positron emission tomography/CT
(FDG-PET/CT)), and treatment response (as assessed by standard of care 3-month post-therapy
FDG-PET/CT).
Stanford is currently not accepting patients for this trial.
For more information, please contact Melissa Usoz, 650-723-8843.
Lead Sponsor
Stanford Investigators
View full details
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Not Recruiting
More
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer
patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study
participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell
carcinoma (RCC) who are receiving antiangiogenesis treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact CCTO, 650-498-7061.
Stanford Investigators
View full details
-
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Not Recruiting
More
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool
for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used
in the 1970s for bone scanning and can be used as a skeletal tracer in current PET/CT
scanners. The combined administration of F-18 and F-18 FDG in a single PET/CT scan for cancer
detection was not attempted to date. We hope to learn what is the best approach for detection
of cancer and thus to improve cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrei Iagaru, 650-736-2859.
Lead Sponsor
Stanford Investigators
View full details
-
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer
Not Recruiting
More
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA)
(gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography
(PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying
prostate cancer that may have returned after a period of improvement (biochemical
recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer
receptor, which can then be imaged by the PET/CT or PET/MRI scanner.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pamela Gallant, 650-736-8965.
Lead Sponsor
Stanford Investigators
View full details
-
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
Not Recruiting
More
The study will be conducted as an open label, single-dose, explorative study with patients
with histologically proven cancer and, preferably, tumor positive lesions in previously
performed nuclear medicine imaging examinations.
The investigational drug will be given as a single administration in a dose of </= 0.1 mg
BAY94-9392 (300 MBq, +/- 10%). The total duration of the study for each patient will be
approximately 8 days.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lindee Burton, 6507254712.
Stanford Investigators
View full details
-
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours
Not Recruiting
More
This was a multicenter, stratified, open, randomized, comparator-controlled, parallel-group
phase III study comparing treatment with Lutathera plus best supportive care (30 mg
Octreotide LAR) to treatment with high dose (60 mg) Octreotide LAR in participants with
metastasized or locally advanced, inoperable, somatostatin receptor positive, histologically
proven midgut carcinoid tumours with progression despite LAR treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Flordeliza Mendoza, 650-724-2056.
Stanford Investigators
View full details
-
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Not Recruiting
More
Advanced Accelerator Applications is currently pursuing marketing approval for
177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to
allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine
tumors, progressive under somatostatin analogue therapy to access the investigational
product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
Not Recruiting
More
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly
diagnosed or recurrent gliomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Andrei Iagaru, 650-736-2859.
Stanford Investigators
View full details
-
Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Not Recruiting
More
This study is a prospective, interventional, open-label, multi-center early access program
for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis
and to collect additional short and long term safety data on the product.
Stanford is currently not accepting patients for this trial.
For more information, please contact Elizabeth Chitouras, 650-498-0623.
Stanford Investigators
View full details
-
Photoacoustic Imaging (PAI) of the Prostate: A Clinical Feasibility Study
Not Recruiting
More
The purpose of our study is to image human prostate tissue using a transrectal photoacoustic
imaging probe.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sri-Rajasekhar Kothapalli, 650-498-7061.
Lead Sponsor
Stanford Investigators
View full details
